| Document |
Document Title |
|
WO/2022/235574A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3 -kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I) or pharmaceutically...
|
|
WO/2022/232459A1 |
This application relates to novel triazole-pyridine substituted pyrrolidinyl, tetrahydro-2H-pyranyl, cyclohexyl, and piperidinyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medi...
|
|
WO/2022/230769A1 |
The present invention addresses the problem of providing a method that enables, at a low cost, production of 5-hydroxymethylfurfural from glucose with a high yield and high selectivity. Said problem is solved by a method that is for prod...
|
|
WO/2022/231172A1 |
The present invention relates to: a multifunctional epoxy compound obtained by modifying two or more epoxide functional groups on terminal portions of liquid crystal molecules synthesized by bonding multiple thermotropic liquid crystal m...
|
|
WO/2022/231299A1 |
The present invention provides: a novel compound which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2022/223750A1 |
The invention provides new heterocyclic compounds having the general formula (I), wherein A, B, X, and R1 to R7 are as described herein, compositions including thecompounds, processes of manufacturing the compounds and methods of using t...
|
|
WO/2022/221194A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2022/214606A1 |
The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the ...
|
|
WO/2022/212489A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2022/206422A1 |
The present invention relates to a compound represented by formula (I). The compound is suitable for use in electronic components, in particular, suitable for use in organic electroluminescent elements. The present invention also relates...
|
|
WO/2022/199662A1 |
Provided are a compound represented by general formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, a deuterium isotopic derivative, pharmaceutically acceptable hydrate, solvate, salt, or eutectic t...
|
|
WO/2022/194236A1 |
Provided herein is novel N-heterocyclic ketones that are useful for treatment of hypertrophic cardiomyopathy (HCM) and other heart diseases. The preparation method thereof, pharmaceutcal compositions comprising the compound.
|
|
WO/2022/192224A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N -oxides, and salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, W, J and Y are as defined in the disclosure. Also disclosed are compositions containing th...
|
|
WO/2022/189810A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/191570A1 |
The present invention relates to a high-efficiency organic light-emitting device having excellent light-emitting characteristics in light-emitting efficiency, etc. by employing an anthracene derivative compound having a characteristic st...
|
|
WO/2022/181508A1 |
The present invention provides: a compound which improves the performance of an organic EL element; an organic electroluminescent element which has improved element performance; and an electronic device which comprises such an organic el...
|
|
WO/2022/171185A1 |
The present invention provides a compound serving as an NLRP3 inhibitor. Specifically, the present invention provides a compound having a structure shown in the following formula (I), or an optical isomer, pharmaceutically acceptable sal...
|
|
WO/2022/171683A1 |
The invention relates to a PAES copolymer (P2) with ionically and/or covalently attached bioactive compound(s), articles comprising (P2), methods of making (P2), and methods for making articles such as membranes comprising (P2). Function...
|
|
WO/2022/170122A1 |
The present disclosure relates compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, ...
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/167631A1 |
The invention provides novel heteroaryl-substituted imidazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1 to R6 are as described herein. Further provided are pharmaceutical ...
|
|
WO/2022/162471A1 |
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
|
|
WO/2022/161496A1 |
The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein variables are as defined as set forth in the specification. The present disclosure also provides compound...
|
|
WO/2022/158442A1 |
The present invention provides, as a radioactive halogen-labeled precursor compound that is highly stable and reactive, a compound represented by general formula (II) [in the formula, R1 and R2 each independently represent an alkyl group...
|
|
WO/2022/157499A1 |
The invention relates to protected HDAC inhibitor compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are as defined herein. In aspects, the inventions relates to use of the compounds, and to methods of deprotecting the compounds.
|
|
WO/2022/150174A1 |
The present invention provides for compounds of Formula (I) (I) wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of...
|
|
WO/2022/148717A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
|
|
WO/2022/139179A1 |
The present invention provides a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/138735A1 |
Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant di...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/135136A1 |
Provided herein are tuberculatin analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
|
|
WO/2022/133027A1 |
Compounds of formula (1) wherein R1 represents a -C(R2)(R3)-[C(R4)(R5)]m-L-R6 group or -R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment o...
|
|
WO/2022/131546A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2022/133031A1 |
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
|
|
WO/2022/124499A1 |
The present specification pertains to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2022/117445A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
|
WO/2022/112345A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/112352A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/114164A1 |
Provided is a compound which is useful as an active ingredient for a pharmaceutical composition for treating cancer associated with the activation of an immunocyte or cancer having resistance to an anti-PD-1 antibody/anti-PD-L1 antibody ...
|
|
WO/2022/114444A1 |
The present invention relates to a novel heterocyclic compound usable in an organic light-emitting device and to an organic light-emitting device comprising same, wherein [chemical formula A] and [chemical formula B] are as described in ...
|
|
WO/2022/108259A1 |
The present specification provides a compound of formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/108068A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/107144A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a disorder associated with binding of IGF2BP1 to an RNA in a subject in need thereof ...
|
|
WO/2022/108258A1 |
The present specification provides a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/105845A1 |
A glucoside derivative, and a preparation method therefor and an application thereof. Specifically, provided is a glucoside derivative, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The ...
|
|
WO/2022/106375A1 |
The present invention provides novel compounds having the general formula (I) wherein A, L, and B are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/105852A1 |
Provided are a triazine dione derivative, a preparation method therefor and an application thereof in medicine. Specifically, provided are a triazine dione derivative represented by general formula (I), a preparation method therefor, a p...
|
|
WO/2022/108141A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/099810A1 |
A tetraphenylethylene compound, an application thereof, and an electronic device using same. The structural general formula of the tetraphenylethylene compound is shown in formula 1. The tetraphenylethylene compound contains an aromatic ...
|
